News
Ozanimod Expands Treatment Options for Ulcerative Colitis in Adult Patients
As a review article published last year in the journal Drugs suggests, ozanimod is an effective and well-tolerated medication for adult patients with moderate to severe ulcerative colitis (UC), both in the initial phase of treatment and in the maintenance phase after achieving remission.
Ozanimod in Induction and Maintenance Therapy for Ulcerative Colitis − True North Study Results
Ozanimod is a selective modulator of the sphingosine-1-phosphate receptor (S1PR) approved for the…
Prognostic Significance of Mutations in Maintenance Hypomethylation Therapy for AML Patients
A recently published sub-analysis of the QUAZAR AML-001 clinical trial evaluated the efficacy of…
Current Recommendations by the ELN Expert Panel on AML Diagnosis Management
The 2022 recommendations from European LeukemiaNet (ELN) add new information to the previous…
Overuse of Corticosteroids as a Serious Problem in ITP
Corticosteroids (CS) are a common part of the treatment for immune thrombocytopenia (ITP). However,…
Romiplostim in Life-Threatening Bleeding Situations − Case Reports
Immune thrombocytopenic purpura, or immune thrombocytopenia (ITP), typically manifests as bleeding…
CYP Enzyme? Cytochrome P450 2D6 and Drug Metabolism
The CYP2D6 isoenzyme of cytochrome P450 participates in the metabolism of approximately 20% of commonly...
Association of M2 Haplotype of the Annexin A5 Gene with Recurrent Reproductive Losses
Annexin A5 (ANXA5) is a placental anticoagulant protein that ensures adequate blood supply to the…
Etiology of Recurrent Reproductive Losses – Focus on Genetics
Repeated pregnancy losses pose a significant threat to a woman's physical and mental health. The…
Li-Fraumeni Syndrome – Indication for Testing and Recommended Surveillance
A germline mutation of the TP53 gene, which causes Li-Fraumeni syndrome, results in a congenital predisposition...